계명대학교 의학도서관 Repository

Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial

Metadata Downloads
Author(s)
Kang, W.C.Ahn, T.Lee, K.Han, S.H.Shin, E.K.Jeong, M.H.Yoon, J.H.Park, J.-S.Bae, J.H.Hur, S.H.Rha, S.W.Oh, S.K.Kim, D.I.Jang, Y.Choi, J.W.Kim, B.O.
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
EuroIntervention
Issued Date
2011
Volume
7
Issue
8
Abstract
Aims: The aim of this study was to compare the efficacy and safety of zotarolimus-eluting stents (ZES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).Methods and results: This study was a prospective, single-blind, multicentre, randomised trial. The primary endpoint was major adverse cardiac events (MACE) at 12 months post-procedure, defined as cardiac death, recurrent myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (TLR). An angiographic substudy was performed at nine months among 348 patients. From October 2006 to April 2008, 611 patients with STEMI undergoing primary PCI were randomly assigned to treatment with ZES (n=205), SES (n=204), or PES (n=202). The cumulative incidence of MACE was 5.9% in the ZES group, 3.4% in the SES group and 5.7% in the PES group at 12-month follow-up (p=0.457). There was a trend towards a lower rate of ischaemia-driven TLR at 12- (p=0.092) and 18-month (p=0.080) follow-up in the SES group compared to the ZES and PES groups. No difference was observed in rates of cardiac death, recurrent MI and combined death and/or recurrent MI among three groups at 12- and 18-month follow-up. The rate of stent thrombosis was similar among the three groups (2.0% in each group, p=1.000).Conclusions: As compared with SES and PES, the use of ZES in patients with STEMI undergoing primary PCI, showed similar rates of MACE, cardiac death and recurrent MI at 12 and 18 months. There was a trend towards a higher rate of TLR with ZES or PES compared to SES. - See more at: http://www.pcronline.com/eurointervention/43rd_issue/volume-7/number-8/148/comparison-of-zotarolimus-eluting-stents-versus-sirolimus-eluting-stents-versus-paclitaxel-eluting-stents-for-primary-percutaneous-coronary-intervention-in-patients-with-st-elevation-myocardial-infarction-results-from-the-korean-multicentre-endeavor-komer-acute-myocardial-infarction-ami-trial.html#sthash.GNPR4e9v.dpuf
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Kang, W.C. et al. (2011). Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention, 7(8), 936–943.
Type
Article
ISSN
1774-024X
Source
https://www.pcronline.com/eurointervention/43rd_issue/volume-7/number-8/148/comparison-of-zotarolimus-eluting-stents-versus-sirolimus-eluting-stents-versus-paclitaxel-eluting-stents-for-primary-percutaneous-coronary-intervention-in-patients-with-st-elevation-myocardial-infarction-results-from-the-korean-multicentre-endeavor-komer-acute-myocardial-infarction-ami-trial.html
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35663
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.